Since obeticholic acid (OCA) was approved by FDA for the treatment of primary biliary cholangitis, research interests are significantly increased in the development of selective FXR modulators to reduce the potential side-effects of the conventional FXR agonist for NASH. This evidence concerns the gene NR1H4 and primary biliary cholangitis.